Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. Winter 2019;64(12):1177-1184.

Combined Lipid-Lowering Therapy

  • PMID: 30704254
Review

Combined Lipid-Lowering Therapy

David Karásek. Vnitr Lek. .

Abstract

Dyslipidemia belongs to the main risk factors for atherosclerosis. To achieve current blood lipid targets, it is often necessary to use intensive hypolipidemic therapy including a combination of individual hypolipidemic drugs. In terms of cardiovascular risk reduction, it is important that the patient is treated with the highest tolerated dose of statin. In the next step, we decide to co-administer ezetimibe and/or fibrate, and for high-risk patients an additional treatment with proprotein convertase subtilisin kexin 9 inhibitors should be considered. The manuscript provides an overview of the individual combinations effectiveness to influence lipid spectrum and the incidence of cardiovascular diseases. Key words: cardiovascular disease - dyslipidemia - ezetimibe - fibrates - PCSK9 inhibitors - statins.

Keywords: cardiovascular disease - dyslipidemia - ezetimibe - fibrates - PCSK9 inhibitors - statins.

Similar articles

See all similar articles

MeSH terms

Feedback